A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER)-Reference-Cited by-同舟云学术

A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER)

Published:2023-02-19 Issue:4 Volume:64 Page:822-834
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Choquette Tricia¹²,Henson Elizabeth S.¹²,Yang Xiaoyan³,Johnston James B.¹⁴,Gibson Spencer B.¹²³

Affiliation:

1. CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, Manitoba, Canada

2. Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada

3. Department of Oncology, University of Alberta, Edmonton, Alberta, Canada

4. Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2171729

Reference21 articles.

1. Cancer Stat Facts: Leukemia – Chronic Lymphocytic Leukemia (CLL). National Cancer Institute, surveillance, epidemiology and end results program; Bethesda MD: National Cancer Institute 2019.

2. Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia

3. Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival

4. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406